Healthcare / BiotechnologyNasdaqCM
$3.00
-0.11 (-3.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-16.5M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$28M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-148.0%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-27.0M · FCF $-23.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | $71667.00 | $374542.00 | $570476.00 | $40189.00 |
| Net Income | $-27.0M | $-27.0M | $-16.3M | $-2.2M | $-5.8M | $-24.1M | $-14.2M | $-11.8M | $-18.4M | $-1.4M | $-18.0M | $-6.7M | $-14.4M | $-2.5M | $-6.9M | $-22.6M | $-8.4M |
| EBITDA | $-28.3M | $-28.3M | $-18.2M | $-7.8M | $-5.8M | $-24.6M | $-15.9M | — | — | — | — | $-6.4M | $-14.0M | $-12.7M | $-11.6M | $-16.4M | $-7.6M |
| EPS | -2.98 | -2.98 | -2.02 | -0.82 | -11.20 | 2920288.50 | 4037397975.00 | 502988175.00 | 243172575.00 | -2183.25 | -1980.00 | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | 37.0% | -304.7% | -423.5% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | -17855.5% | -3148.3% | -2879.9% | -19002.6% |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | -3429.7% | -1833.9% | -3967.9% | -20925.1% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | — | — | -0.37 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.36 | 3.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-23.4M | $-23.4M | $-16.5M | $-7.4M | $-2.6M | — | — | — | — | $-12.8M | $-10.8M | $-5.2M | $-9.1M | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -148.0% | -148.0% | -41.6% | -29.4% | 17.4% | -69.0% | -57.2% | -58.6% | -117.7% | -6.4% | -196.4% | 16143.1% | -37.6% | -38.1% | 37.4% | 140.9% | — |
| Valuation | |||||||||||||||||
| P/B | 1.49 | 1.49 | 0.48 | 3.39 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | — | — | — | -80.9% | -34.3% | 1319.5% | — |
| EPS Growth | -47.5% | -47.5% | -146.3% | 92.7% | — | -99.9% | 702.7% | 106.8% | 11138200.3% | -10.3% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-58.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.02 → -2.98
Residual
-58.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.